4X69

Crystal structure of OP0595 complexed with CTX-M-44

4X69 の概要

• エントリーDOI: 10.2210/pdb4x69/pdb
• 関連するPDBエントリー: 4X68
• 分子名称: Beta-lactamase Toho-1, (2S,5R)-N-(2-aminoethoxy)-1-formyl-5-[(sulfooxy)amino]piperidine-2-carboxamide, 1,2-ETHANEDIOL, ... (4 entities in total)
• 機能のキーワード: hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• 由来する生物種: Escherichia coli
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 57272.68

構造登録者

Yamada, M.,Watanabe, T. (登録日: 2014-12-07, 公開日: 2015-07-01, 最終更新日: 2024-10-23)

主引用文献

Morinaka, A.,Tsutsumi, Y.,Yamada, M.,Suzuki, K.,Watanabe, T.,Abe, T.,Furuuchi, T.,Inamura, S.,Sakamaki, Y.,Mitsuhashi, N.,Ida, T.,Livermore, D.M.
OP0595, a new diazabicyclooctane: mode of action as a serine beta-lactamase inhibitor, antibiotic and beta-lactam 'enhancer'
J.Antimicrob.Chemother., 70:2779-2786, 2015

PubMed Abstract: The production of a growing diversity of β-lactamases by Gram-negative bacteria challenges antimicrobial chemotherapy. OP0595, discovered separately by each of Meiji Seika Pharma and Fedora Pharmaceuticals, is a new diazabicyclooctane serine β-lactamase inhibitor that also acts as an antibiotic and as a β-lactamase-independent β-lactam 'enhancer'.

PubMed: 26089439
DOI: 10.1093/jac/dkv166

実験手法

X-RAY DIFFRACTION (1.42 Å)